Long-term 52-week results of PALACE 3, a phase 3, randomized controlled trial of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement
Servizos
Servizos
Data de publicación
2014Título da revista
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY
Tipo de contido
Publicación de congreso
